Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.34 and traded as high as $3.56. Voyager Therapeutics shares last traded at $3.54, with a volume of 406,199 shares traded.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Price Performance

The firm’s fifty day moving average price is $3.34 and its 200-day moving average price is $3.68. The company has a market capitalization of $218.13 million, a price-to-earnings ratio of -1.97 and a beta of 1.31.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08. The company had revenue of $3.17 million for the quarter, compared to analyst estimates of $4.52 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%. On average, research analysts predict that Voyager Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. BlackRock Inc. acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at $18,102,000. EcoR1 Capital LLC increased its position in Voyager Therapeutics by 497.2% in the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after buying an additional 3,332,544 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Voyager Therapeutics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock valued at $15,178,000 after buying an additional 40,147 shares in the last quarter. Opaleye Management Inc. purchased a new stake in shares of Voyager Therapeutics in the fourth quarter worth about $4,704,000. Finally, Erste Asset Management GmbH boosted its stake in Voyager Therapeutics by 7.0% during the fourth quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock valued at $4,718,000 after buying an additional 78,348 shares during the period. 48.03% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.